Wolverine Trading
BMRN icon

Wolverine Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History

Wolverine Trading’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$456K Buy
8,435
+3,346
+66% +$191K ﹤0.01% 3817
2025
Q2 		$281K Buy
+5,089
New +$300K ﹤0.01% 3552
2024
Q4 		– Sell
-20,927
Closed -$1.4M – 5284
2024
Q3 		$1.48M Buy
+20,927
New +$1.75M ﹤0.01% 1982
2024
Q2 		– Sell
-10,225
Closed -$893K – 4506
2024
Q1 		$893K Buy
+10,225
New +$915K ﹤0.01% 2304
2023
Q3 		– Sell
-14,656
Closed -$1.3M – 4518
2023
Q2 		$1.3M Buy
+14,656
New +$1.38M ﹤0.01% 1800
2022
Q4 		– Sell
-9,237
Closed -$867K – 4021
2022
Q3 		$786K Sell
9,237
-5,601
-38% -$499K ﹤0.01% 2182
2022
Q2 		$1.25M Buy
14,838
+781
+6% +$62.2K ﹤0.01% 1743
2022
Q1 		$1.09M Sell
14,057
-5,709
-29% -$478K ﹤0.01% 2349
2021
Q4 		$1.76M Buy
19,766
+4,665
+31% +$385K ﹤0.01% 2009
2021
Q3 		$1.16M Sell
15,101
-717
-5% -$56.6K ﹤0.01% 2802
2021
Q2 		$1.32M Sell
15,818
-957
-6% -$75.9K ﹤0.01% 2463
2021
Q1 		$1.26M Buy
16,775
+4,590
+38% +$375K ﹤0.01% 2463
2020
Q4 		$1.06M Sell
12,185
-6,332
-34% -$502K ﹤0.01% 2304
2020
Q3 		$1.41M Buy
18,517
+13,696
+284% +$1.39M ﹤0.01% 1760
2020
Q2 		$589K Sell
4,821
-253
-5% -$25.1K ﹤0.01% 2562
2020
Q1 		$419K Sell
5,074
-389
-7% -$33.5K ﹤0.01% 2859
2019
Q4 		$462K Buy
5,463
+1,296
+31% +$97.9K ﹤0.01% 3140
2019
Q3 		$285K Buy
+4,167
New +$321K ﹤0.01% 3215
2018
Q4 		– Sell
-9,954
Closed -$947K – 4440
2018
Q3 		$965K Buy
9,954
+2,096
+27% +$209K ﹤0.01% 2406
2018
Q2 		$637K Hold
7,858
– – ﹤0.01% 2774
2018
Q1 		$637K Buy
+7,858
New +$674K ﹤0.01% 2774
2016
Q4 		– Sell
-3,439
Closed -$296K – 4445
2016
Q3 		$319K Buy
3,439
+36
+1% +$3.39K ﹤0.01% 3148
2016
Q2 		$267K Buy
+3,403
New +$289K ﹤0.01% 2928

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wolverine Trading's BMRN Position: Q3 2025 in Review

Wolverine Trading increased its BioMarin Pharmaceuticals (BMRN) stake by 66% in Q3 2025, buying an estimated $191K and bringing the position to 8,435 shares worth $456K. The position accounts for ﹤0.01% of the portfolio, ranked #3817.

Wolverine Trading first reported a position in BMRN in Q2 2016 and has held it in 23 quarters since. The position peaked at $1.76M in Q4 2021. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

  • Wolverine Trading held 8,435 shares of BioMarin Pharmaceuticals worth $456K as of Q3 2025.
  • Wolverine Trading bought 3,346 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $191K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #3817 holding.
  • Wolverine Trading first reported a position in BioMarin Pharmaceuticals in Q2 2016 and has held it in 23 quarters since.
  • Wolverine Trading's BioMarin Pharmaceuticals position peaked at $1.76M in Q4 2021.
  • 576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.